KYTX Stock Analysis: Buy, Sell, or Hold?
KYTX - Kyverna Therapeutics, Inc. Common Stock
$7.51
0.21 (2.88%)
▲
5d:
-5.18%
30d:
-15.52%
90d:
-15.33%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KYTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KYTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $7.51, which is considered slightly low relative to its 30-day fair value range of $7.25 to $8.94.
Technical Outlook: Technically, KYTX is in a downtrend. Immediate support is located at $6.98, while resistance sits at $8.14.
Market Sentiment: KYTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.40 (+316.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KYTX is in a downtrend. Immediate support is located at $6.98, while resistance sits at $8.14.
Market Sentiment: KYTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.40 (+316.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.25 -
$8.94
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 316.4% below Wall St target ($30.40)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$7.25 -
$8.94
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.89
(11.8%)
Support & Resistance Levels
Support Level
$6.98
Resistance Level
$8.14
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.47
Wall Street Target
$30.40
(+316.4%)
Share & Embed Analysis
Last updated: August 04, 2026 2:41 AM ET
Data refreshes hourly during market hours. Next update: 3:41 AM
Data refreshes hourly during market hours. Next update: 3:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
